momentumstudy.bsky.social @momentumstudy.bsky.social · 04/08/2025Thrilled to share that the DESTINATION 2 trial has received the green light for recruitment at The Christie! Looking forward to welcoming patients and making meaningful progress together #clinicaltrials #thechristie #oncologyresearch #prostatecancer 010
Reposted by @momentumstudy.bsky.socialRTTQA @rttqa.bsky.social · 05/05/2025Congratulations to our very own Liz Miles, incredible colleague, mentor & friend on her #ESTRO25 Interdisciplinary Award. A true champion for #collaboration and #RTQA. So well deserved- we could not be prouder! 0114
Reposted by @momentumstudy.bsky.socialRTTQA @rttqa.bsky.social · 21/04/2025Regional LN delineation variability in #BrCa RT within the Fast Forward trial. Despite this variability, all mandatory constraints were adhered to. #RTQA plays a central role in providing support & guidance to participating centres www.sciencedirect.com/science/arti...sciencedirect.comRegional Lymph Node Delineation variability and its Dosimetric Impact in Breast Cancer RadiotherapyTo quantify the interobserver variability of regional lymph node delineation for breast cancer radiotherapy (RT) and establish whether a relationship … 143
momentumstudy.bsky.social @momentumstudy.bsky.social · 02/04/2025We are thrilled to announce opening of the ANDROMEDA study! This represents another significant achievement stemming from MOMENTUM infrastructure. We’re excited to leverage our advanced Unity MR-Linac capabilities to deliver dose-escalated adaptive radiotherapy for patients with rectal cancer. 010
momentumstudy.bsky.social @momentumstudy.bsky.social · 11/03/2025Happy to announce that the 7000th participant for MOMENTUM has been enrolled at UMC Utrecht yesterday! 030
Reposted by @momentumstudy.bsky.socialJohn Christodouleas @xristodouleas.bsky.social · 16/02/2025For muscle-invasive bladder cancer, the Lancet Oncology paper by Zlotta et al is the best comparative effectiveness study of TMT versus RC. How can we use this study to communicate the risks of delayed cystectomy to patients? Peppin A et al provide an answer at GU ASCO 2025: 011
Reposted by @momentumstudy.bsky.socialUCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 14/02/2025#GU25 #OncSky #MedSky 001
momentumstudy.bsky.social @momentumstudy.bsky.social · 11/02/2025www.phiro.science/article/S240... Another elegant demonstration of how simplifying complex workflows yields powerful results. By leveraging MOMENTUM's infrastructure, this team shows streamlined adaptive radiotherapy maintains quality while reducing treatment times. Congratulations!phiro.scienceA simplified online adaptive workflow for long-course magnetic resonance-guided radiotherapy in esophageal cancerSince the publication of the landmark CROSS trial in 2012 [1], neoadjuvant chemoradiotherapy has become a cornerstone in the curative treatment of esophageal cancer in much of the western world. The r... 110
